VACBF (Nykode Therapeutics AS) Institutional Ownership: 15.27% (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VACBF Nykode Therapeutics AS VACBF
22 GF Score
Price $0.32
GF Value $0.76
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Nykode Therapeutics AS Institutional Ownership?

Nykode Therapeutics AS VACBF -1.05% 22 Institutional Ownership is 15.27% as of Jul. 19, 2026. GuruFocus rates VACBF with a GF Score™ of 22/100 and a GF Value™ of $0.76 (Possible Value Trap). The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nykode Therapeutics AS's institutional ownership is 15.27%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nykode Therapeutics AS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nykode Therapeutics AS's Float Percentage Of Total Shares Outstanding is 0.00%.

Nykode Therapeutics AS Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Institutional Ownership Chart

Nykode Therapeutics AS Historical Data

The historical data trend for Nykode Therapeutics AS can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 11.29 11.31 10.17 10.51 10.46 10.46 10.47 10.64 11.67 11.76
VACBF
22GF Score
Nykode Therapeutics AS VACBF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 15.27% mean?
Nykode Therapeutics AS (VACBF) has a Institutional Ownership of 15.27% as of Jul. 19, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Institutional Ownership too high?
Nykode Therapeutics AS's current Institutional Ownership is 15.27%. Overall, Nykode Therapeutics AS has a GF Score™ of 22/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Institutional Ownership compare to VRTX and REGN?
Nykode Therapeutics AS's Institutional Ownership of 15.27% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Institutional Ownership is 15.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (VACBF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.76, compared to a current price of $0.32 — trading 57.7% below its estimated fair value. The current Institutional Ownership is 15.27%. Nykode Therapeutics AS's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Nykode Therapeutics AS (VACBF), the current Institutional Ownership is 15.27% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (VACBF) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of $0.32 is trading 57.7% below its estimated GF Value™ of $0.76. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for VACBF:

  • Institutional Ownership: 15.27%
  • GF Value™: $0.76 vs. price of $0.32 (57.7% below fair value)
  • GF Score™: 22/100 with 1 warning sign

No single metric tells the full story. See the VACBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
22GF Score

Get the complete analysis for VACBF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price
$0.76
GF Value